Giant congenital exophytic strawberry-like mass in a newborn

C. Carnevale,1 A. Diociaiuti,1 C. Retrosi,1 G. Gualdi,2,3 A. Fabiano,3,4 A. Stracuzzi5 and M. El Hachem1

Clinical findings

A male newborn was referred at birth because of a suspected giant congenital haemangioma on his back. He had been delivered vaginally at 38 + 5 weeks after a normal pregnancy. Ultrasonography during the fifth month of pregnancy had not detected the mass; however, at birth, a purplish-red, reniform, nodular and pedunculated skin tumour measuring 80 × 50 × 35 mm was visible on the right paravertebral lumbosacral area. This strawberry-like mass had a tense consistency and a smooth surface with homogeneous, diffuse and yellowish point depressions (Fig. 1a,b). Doppler ultrasonography showed that the tumour was not vascular in nature. Complete surgical excision was performed and the tumour was sent for histology.

Histopathological findings

Histological examination showed a well-circumscribed dermal lesion composed of multiple folliculosebaceous units, with frequent cystic dilated hair infundibules (Fig. 2a). The units were embedded in a loose fibromyxoid stroma with interspersed thin smooth muscle bundles, which were nicely highlighted by desmin. Small lobules of immature adipose tissue were scattered within the stroma (Fig. 2b). Small nerve trunks and ectatic vessels were also seen (Fig. 2c). No connections between the sebaceous lobules and the overlying epidermis were noted. At the periphery, a stromal cleft separated the lesion from the surrounding dermis.

What is your diagnosis?

Correspondence: Dr Claudia Carnevale, Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy

Conflict of interest: the authors declare that they have no conflicts of interest.

Accepted for publication 21 June 2021
Diagnosis

Folliculosebaceous cystic hamartoma (FSCH).

Discussion

FSCH, first described in 1991 by Kimura et al.,\(^1\) is an uncommon benign skin lesion, with < 100 cases reported in the literature since the first description. FSCH usually manifests with a single, small (5–15 mm), flesh-coloured, sessile or pedunculated mass, frequently located on the head, in particular on the central part of the face and nose. FSCH is usually isolated, and a syndromic form has never been reported in the literature. It primarily affects middle-aged adults,\(^1\)\(^–\)\(^2\) but has also been described in infancy and a very few congenital cases have been reported.\(^3\)\(^–\)\(^5\) Emsen and Livaoglu described a case of FSCH appearing at 6 months of age as a congenital case.\(^6\)

According to previous reports, FSCH is defined ‘giant’ when the lesion ranges from 50 to 230 mm in diameter,\(^2\) and only a very small number of giant FSCH have been reported.\(^2\)\(^–\)\(^6\) Congenital FSCH were described as ‘giant’ in only three cases, with the patients being 6, 9 and 12 months of age; however, the lesions were smaller at birth in all three cases.\(^3\)\(^–\)\(^5\)

To our knowledge, our patient is the first case of congenital FSCH that was giant since birth.

FSCH is considered a hamartoma because of the coexistence of multiple mature ectodermal and mesodermal elements. Histological examination is necessary to define the diagnosis. Whereas the clinical aspects and the localization are characteristic in adults, there are variations in its appearance in newborns and children. CO\(_2\) laser, oral acitretin and surgery are the most useful therapeutic options.\(^1\)\(^–\)\(^6\) Our patient was treated with excision surgery, and has been in good health since then.

Acknowledgement

We thank the patient’s family for their informed consent for publication of their child’s case and photographs. We thank G. Bacile for the preparation of the figures. Three of the authors (CC, AD, MEH) of this publication are members of the Reference Network for Rare Skin Diseases (ERN-Skin).

Learning points

- FSCH is an uncommon hamartoma.
- It is usually seen in middle-aged adults and rarely described in children.
- Congenital FSCH has been reported in very few cases, and giant congenital FSCH is an extremely rare entity.
- Histopathology is necessary to establish the diagnosis.
References

1 Kimura T, Miyazawa H, Aoyagi T et al. Folliculosebaceous cystic hamartoma. A distinctive malformation of the skin. Am J Dermatopathol 1991; 13: 213–20.
2 Haw S, Lee MU. A case of giant folliculosebaceous cystic hamartoma. Ann Dermatol 2009; 21: 63–5.
3 Ceballos-Rodriguez MC, Campos-Dominguez M, Parra-Blanco V et al. A giant congenital folliculosebaceous cystic hamartoma. J Am Acad Dermatol 2015; 72(Suppl): 196.
4 Cole P, Kaufman Y, Dishop M et al. Giant, congenital folliculosebaceous cystic hamartoma: a case against a pathogenetic relationship with trichofolliculoma. Am J Dermatopathol 2008; 30: 500–3.
5 Bobde VM, Helwatkar SB, Sathawane PR et al. Congenital giant folliculosebaceous cystic hamartoma of thigh: a rare case. Indian J Dermatol 2019; 64: 490–2.
6 Emsen IM, Livaoglu A. An uncommon folliculosebaceous cystic hamartoma on the lower extremity. Can J Plast Surg 2007; 15: 231–3.

CPD questions

Learning objective

To gain up-to-date knowledge on the classification of and investigations for folliculosebaceous cystic hamartoma.

Question 1

Why is folliculosebaceous cystic hamartoma (FSCH) defined as a hamartoma?

(a) Because of the coexistence of multiple mature ectodermal and mesodermal elements.
(b) Because of the strawberry-like appearance.
(c) Because FSCH is a congenital tumour.
(d) Because FSCH is a benign tumour.
(e) Because of the proliferation of multiple sebaceous glands.

Question 2

What is the most useful investigation for diagnosis of folliculosebaceous cystic hamartoma (FSCH)?

(a) Clinical examination.
(b) Magnetic resonance imaging.
(c) Ecocolour Doppler.
(d) Histology.
(e) Dermoscopy.

Instructions for answering questions

This learning activity is freely available online at http://www.wileyhealthlearning.com/ced

Users are encouraged to

- Read the article in print or online, paying particular attention to the learning points and any author conflict of interest disclosures.
- Reflect on the article.
- Register or login online at http://www.wileyhealthlearning.com/ced and answer the CPD questions.
- Complete the required evaluation component of the activity.

Once the test is passed, you will receive a certificate and the learning activity can be added to your RCP CPD diary as a self-certified entry.

This activity will be available for CPD credit for 2 years following its publication date. At that time, it will be reviewed and potentially updated and extended for an additional period.